The enrolled patients were divided into two groups: patients who received prophylactic pegfilgrastim administration, 36 (42.4%) (PEG(+)), and those who received chemotherapy only with the contemporary G-CSF agent, filgrastim, which was administered when they suffered from FN or severe neutropenia, 49 (57.6%) (PEG(-)). Here, CSF3 is linked to Decreased total neutrophil count.